hurriyet.com.tr / FOREIGN NEWS
The world, which has been fighting the coronavirus for more than 2 years, is now on alert for the Omicron sub-variant BA.5. The countdown has begun for the specific vaccine for this sub-variant. Bad news came from the drug, which was developed with the hope of completely eliminating the epidemic from our lives.
Coming into our lives in the last months of 2019 coronavirus (Covid-19) World It has cost millions of lives across the country.
The virus, which causes us to leave many of our habits behind, continues to change its shell, so to speak.
While many countries decided to relax after the more contagious but less lethal Omicron variant, the virus reminded itself once again with BA.4 and BA.5 sub-variants.
Because nearly two and a half years after the start of the pandemic, we are facing the most contagious variant ever.
BioNTech and Pfizeradapted to Omicron’s BA.4 and BA.5 variants Covid-19 Countdown to vaccination
Two new companies corona Bad news from Paxlovid as he prepares to begin clinical testing for his vaccine
Global experts state that a new wave may be experienced in the pandemic and reiterate the warning that the fight against Covid-19 is not over yet.class=”medianet-inline-adv”>
Pfizer, which produces the Corona vaccine with German BioNTech, announced that the drug called Paxlovid, which it developed specifically against coronavirus, reduces the rate of hospitalization and death by close to 90 percent in those who are at risk of having a severe disease.
However, the latest news has made the effectiveness of the drug debatable. According to the news in USA Today, recent tests concluded that Paxlovid showed little benefit in young adults.
NO MEASURABLE BENEFITS
Results from a study involving 109,000 patients in Israel showed no measurable benefit in people aged 40 to 65 years using this drug.
But the researchers found that Paxlovid reduced hospitalizations by roughly 75 percent in people 65 and older when given shortly after infection.
US 10 BILLION DOLLARS SPENDED
The Biden administration spent more than $10 billion buying the drug and making it available in thousands of pharmacies.
.